Skip to main content

Advertisement

SpringerLink
Log in

Immunomodulation does not alter histology in resected Crohn’s disease

  • Original Article
  • Published:
Techniques in Coloproctology Aims and scope Submit manuscript

Abstract

Background

The use of immunomodulators (Azathioprine, 6-Mercaptopurine and Methotrexate) and biological agents (Infliximab and adalimumab) for the treatment of Crohn’s disease (CD) has increased in the recent years with the aim of treating the inflammatory component of the disease and hoping to change the natural history of the disease. The aim of this study was to determine if the use of immunomodulators or biological agents in the 2 years prior to resection affects the histopathological characteristics of the patient’s disease.

Methods

A retrospective review was conducted over a 10-year period (1996–2005) of patients who underwent resection for CD. Clinical case notes and histology specimens were reviewed. Patients treated with Azathioprine, 6-Mercaptopurine, Methotrexate or Infliximab for more than 3 months within the 2 years preceding surgery were deemed to have been immunomodulated. The results were also analysed by Montreal phenotype.

Results

A total of 165 patients were identified. 52 patients had been treated with either immunomodulator or biological agent. Of 20 histological features examined, only muscular hypertrophy approached significance (P = 0.05), Montreal A and Montreal L phenotypes were the same regardless on immunomodulators, however, there was a significant difference (P = 0.03) with regard to Montreal B in patients with stricturing disease being more likely to have received an immunomodulator.

Conclusions

In this cohort of patients requiring resection for CD, those with stricturing disease were more likely to receive immunomodulators or biologics than those without stricturing disease. However, there were no significant histological differences in the resected specimens between those who did and those who did not receive these drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Gearry RB, Richardson A, Frampton CM et al (2006) High incidence of Crohn’s disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 12:936–943

    Article  PubMed  Google Scholar 

  2. Baumgart DC, Carding SR (2007) Inflammatory bowel disease: cause and immunobiology. Lancet 369:1627–1640

    Article  CAS  PubMed  Google Scholar 

  3. Rutgeerts P, Goboes K, Peeters M et al (1991) Effect of faecal stream diversion on recurrence of Crohn’s disease in the neoterminal ileum. Lancet 338:771–774

    Article  CAS  PubMed  Google Scholar 

  4. Krishnan A, Korzenik JR (2002) Inflammatory bowel disease and environmental influences. Gastroenterol Clin North Am 31:21–39

    Article  PubMed  Google Scholar 

  5. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448:427–434

    Article  CAS  PubMed  Google Scholar 

  6. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R (1995) A controlled double blind study of Azathioprine in the management of Crohn’s disease. Gut 37:674–678

    Article  CAS  PubMed  Google Scholar 

  7. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS (1980) Treatment of Crohn’s disease with 6-Mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 302:981–987

    CAS  PubMed  Google Scholar 

  8. Feagan BG, Rochon J, Fedorak RN et al (1995) Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 332:292–297

    Article  CAS  PubMed  Google Scholar 

  9. Alfadhli AA, McDonald JW, Feagan BG (2005) Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev. CD003459

  10. Feagan BG, Fedorak RN, Irvine EJ et al (2000) A comparison of Methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 342:1627–1632

    Article  CAS  PubMed  Google Scholar 

  11. Present DH, Rutgeerts P, Targan S et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405

    Article  CAS  PubMed  Google Scholar 

  12. Sands BE, Anderson FH, Bernstein CN et al (2004) Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 350:876–885

    Article  CAS  PubMed  Google Scholar 

  13. Hanauer SB, Feagan BG, Lichtenstein GR et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549

    Article  CAS  PubMed  Google Scholar 

  14. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP (2005) Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 54:237–241

    Article  CAS  PubMed  Google Scholar 

  15. D’Haens G, Geboes K, Ponette E, Penninckx F, Rutgeerts P (1997) Healing of severe recurrent ileitis with Azathioprine therapy in patients with Crohn’s disease. Gastroenterology 112:1475–1481

    Article  PubMed  Google Scholar 

  16. D’Haens G, Van Deventer S, Van Hogezand R et al (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 116:1029–1034

    Article  PubMed  Google Scholar 

  17. Stange EF, Travis SP, Vermeire S et al (2006) European evidence based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut 55(Suppl 1):11–15

    Google Scholar 

  18. D’Haens G, Geboes K, Rutgeerts P (1999) Endoscopic and histologic healing of Crohn’s (ileo-) colitis with Azathioprine. Gastrointest Endosc 50:667–671

    Article  PubMed  Google Scholar 

  19. Geboes K, Rutgeerts P, Opdenakker G et al (2005) Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn’s disease. Curr Med Res Opin 21:1741–1754

    Article  CAS  PubMed  Google Scholar 

  20. Arnott ID, Watts D, Ghosh S (2002) Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn’s disease? Aliment Pharmacol Ther 16:857–867

    Article  CAS  PubMed  Google Scholar 

  21. Allez M, Lemann M, Bonnet J, Cattan P, Jian R, Modigliani R (2002) Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 97:947–953

    PubMed  Google Scholar 

  22. D’Haens G (2004) Mucosal healing in pediatric Crohn’s disease: the goal of medical treatment. Inflamm Bowel Dis 10:479–480

    Article  PubMed  Google Scholar 

  23. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I (2000) Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119:15–22

    Article  CAS  PubMed  Google Scholar 

  24. D’Haens GR, Gasparaitis AE, Hanauer SB (1995) Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn’s disease. Gut 36:715–717

    Article  PubMed  Google Scholar 

  25. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J (2006) The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 24:319–330

    Article  CAS  PubMed  Google Scholar 

  26. Irving PM, Gearry RB, Sparrow MP, Gibson PR (2007) Review article: appropriate use of corticosteroids in Crohn’s disease. Aliment Pharmacol Ther 26:313–329

    Article  CAS  PubMed  Google Scholar 

  27. Tiede I, Fritz G, Strand S et al (2003) CD28-dependent Rac1 activation is the molecular target of Azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111:1133–1145

    CAS  PubMed  Google Scholar 

  28. Nathan DM, Iser JH, Gibson PR (2008) A single center experience of Methotrexate in the treatment of Crohn’s disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol 23:954–958

    Article  CAS  PubMed  Google Scholar 

  29. Rutgeerts P, Diamond RH, Bala M et al (2006) Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 63:433–442 Quiz 64

    Article  PubMed  Google Scholar 

  30. Rutgeerts P, Feagan BG, Lichtenstein GR et al (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126:402–413

    Article  CAS  PubMed  Google Scholar 

  31. Geboes K, Dalle I (2002) Influence of treatment on morphological features of mucosal inflammation. Gut 50(Suppl 3):III37–III42

    Article  PubMed  Google Scholar 

  32. Mary JY, Modigliani R (1989) Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 30:983–989

    Article  CAS  PubMed  Google Scholar 

  33. Gomes P, du Boulay C, Smith CL, Holdstock G (1986) Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 27:92–95

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Colorectal Unit, Department of Surgery, Christchurch Hospital, Riccarton Ave, Christchurch, New Zealand

    F. A. Frizelle, A. Ing & B. Dobbs

  2. Department of Gastroenterology, Christchurch Hospital, Christchurch, New Zealand

    R. B. Gearry

  3. Department of Pathology, Christchurch Hospital, Christchurch, New Zealand

    M. Whitehead

  4. Department of Surgery, Western Hospital, Footscray, Melbourne, Australia

    I. G. Faragher

  5. University of Otago, Christchurch, New Zealand

    F. A. Frizelle & R. B. Gearry

Authors
  1. F. A. Frizelle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Ing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. B. Gearry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Whitehead
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. G. Faragher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Dobbs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. A. Frizelle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frizelle, F.A., Ing, A., Gearry, R.B. et al. Immunomodulation does not alter histology in resected Crohn’s disease. Tech Coloproctol 13, 295–300 (2009). https://doi.org/10.1007/s10151-009-0538-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10151-009-0538-7

Keywords

Search

Navigation